An ambitious project led by Vanderbilt University Medical Center investigators aims to use artificial intelligence technologies to generate antibody therapies against any antigen target of interest.

Craft Capital Management LLC acted as underwriter for the Offering (the “Underwriter”). VCL Law LLP acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities ...

Greenhaven Road Capital, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the ...

The global meningitis treatment industry, valued at USD 150.9 million in 2023, is projected to grow at a CAGR of 4.1% from ...

Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, ...

CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD -- Flexible Dosing and Extended Duration would be Important ...